Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$319.66 USD

319.66
1,467,828

+2.18 (0.69%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer

by Zacks Equity Research

FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.

Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention

by Zacks Equity Research

The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.

Why Is Amgen (AMGN) Up 0.8% Since Last Earnings Report?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer

by Zacks Equity Research

The CHMP recommends approval of Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy for the first-line treatment of esophageal and gastroesophageal junction carcinoma in Europe.

Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DEF

Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics

by Zacks Equity Research

Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics

Ekta Bagri headshot

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

by Ekta Bagri

The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen

Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More

by Zacks Equity Research

The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.

Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong

by Zacks Equity Research

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

Radius (RDUS) Q1 Loss Narrower than Expected, Revenues Lag

by Zacks Equity Research

Radius (RDUS) reports a narrower loss but misses on sales in the first quarter as lead drug sales decline.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to These Q1 Earnings Releases?

by Sweta Jaiswal, FRM

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales

by Zacks Equity Research

Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021. Stock up.

Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales

by Zacks Equity Research

Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.

AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance

by Zacks Equity Research

AbbVie (ABBV) beats on first-quarter 2021 earnings and revenues. Shares up in pre-market trading.

Stock Market News for Apr 29, 2021

by Zacks Equity Research

Markets closed lower on Wednesday after the Fed at the end of its two-day policy meeting decided to keep interest rates unchanged and the monetary policy easy despite the economy strengthening.

Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DEF

Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News

by Zacks Equity Research

The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.

Amgen (AMGN) Q1 Earnings, Sales Miss on Low Prices, Stock Down

by Zacks Equity Research

Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.

Amgen (AMGN) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of -7.50% and -5.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo

by Zacks Equity Research

Lilly (LLY) plans to stop COVID-19 treatment with bamlanivimab alone in the United States. Instead, a combination of bamlanivimab and etesevimab will be available for the same, a better therapy for variants.

Stock Market News for Apr 16, 2021

by Zacks Equity Research

Benchmark hit new records on Thursday as rebound in consumer spending and a buoyant jobs market attested economic recovery along with better-than-expected Q1 earnings reports.